Clinical Trial Update: Panitumumab, Combination Chemotherapy, & Radiation Therapy in Esophageal or Gastroesophageal Junction Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial investigating panitumumab with combination chemotherapy and radiation therapy for esophageal or gastroesophageal junction adenocarcinoma; study te…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer
• Gastroesophageal Junction Cancer

Drugs mentioned

• Panitumumab (panitumumab)

Snippet

Sponsor: University of Nebraska | Conditions: Adenocarcinoma of the Gastroesophageal Junction, Esophageal Adenocarcinoma | Phase 2 | Status: TERMINATED | Results posted: 2018-03-13